NGM ($NASDAQ:NGM) Biopharmaceuticals reported total revenue of USD 1.4 million for the quarter ending on June 30 2023, which was a decrease of 82.9% from the corresponding quarter of the prior year on August 3 2023. Net income for the same period was USD -38.3 million, a decrease from -46.5 million in the comparative quarter of the previous year.
GoodWhale can be used to analyze the fundamentals of NGM BIOPHARMACEUTICALS. This analysis provides a risk rating for this investment, which is classified as medium risk in terms of financial and business aspects. GoodWhale has detected 2 risk warnings in the balance sheet and cashflow statement. These warnings could indicate potential investments risks, and it is recommended to register on goodwhale.com to check them out. It is also important to remember that no investment is completely without risks, but being aware of the possible risks can help investors make more informed decisions. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Ngm Biopharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Ngm Biopharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Ngm Biopharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Ngm Biopharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The company discovers and develops next-generation medicines for the treatment of serious diseases. Its product candidates include NGM282, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis; NGM355, which is in Phase I/II clinical trials for the treatment of cholestatic liver diseases; and NGM120, which is in Phase I/II clinical trials for cancer. The company has collaborations with Merck Sharp & Dohme Corp., Sanofi, Alexion Pharmaceuticals, Inc., and Pfizer Inc. NGM Biopharmaceuticals Inc. was founded in 2007 and is headquartered in South San Francisco, California. NGM Biopharmaceuticals Inc’s main competitors are Provention Bio Inc, Axsome Therapeutics Inc, Aileron Therapeutics Inc. All three companies are clinical-stage biopharmaceutical companies that focus on the discovery and development of next-generation medicines for the treatment of serious diseases.
Prevention Bio Inc is a clinical stage biopharmaceutical company developing products to prevent and treat serious infections. The company has a market cap of 722.81M as of 2022 and a Return on Equity of -63.25%. Prevention Bio Inc’s products are based on its proprietary platform technology, which is designed to target and kill pathogenic bacteria, viruses and fungi. The company’s lead product candidate is PREV-001, a prophylactic vaccine for the prevention of Clostridium difficile infection. Prevention Bio Inc is headquartered in San Diego, California.
– Axsome Therapeutics Inc ($NASDAQ:AXSM)
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in developing novel therapies for the management of central nervous system (CNS) disorders. The company’s product pipeline includes treatments for Alzheimer’s disease, migraine, and depression. As of 2022, Axsome’s market cap is $2.56 billion and its ROE is -110.46%.
Axsome’s negative ROE is due to the fact that the company is not yet profitable. In 2020, Axsome reported a net loss of $103.8 million. The company’s clinical-stage product pipeline and large market potential make it a risky investment, but one with potential high rewards.
– Aileron Therapeutics Inc ($NASDAQ:ALRN)
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on the development of drugs to treat cancer and other diseases. The company’s market cap is $305.62M and its ROE is -56.6%. Aileron’s main product candidate is ALRN-6924, which is in clinical trials for the treatment of solid tumors.
Despite the decline, their stock price moved up on the same day, indicating investor confidence in the company. It will be important to keep an eye on future earnings to get an understanding of how this firm is performing and whether this positive sentiment is justified.